Dynatrace, Inc reports results for the quarter ended June 30 - Earnings Summary
Dynatrace, Inc reports results for the quarter ended June 30 - Earnings Summary
Dynatrace, Inc DT.N reported quarterly adjusted earnings of 48 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of 42 cents. The mean expectation of thirty four analysts for the quarter was for earnings of 45 cents per share. Wall Street expected results to range from 44 cents to 49 cents per share.
Revenue rose 16.2% to $554.55 million from a year ago; analysts expected $550.04 million.
Dynatrace, Inc's reported EPS for the quarter was 12 cents.
The company reported quarterly net income of $36.65 million.
Dynatrace, Inc shares had risen by 4.1% this quarter and gained 5.5% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 1.4% in the last three months.
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 26 "strong buy" or "buy," 11 "hold" and no "sell" or "strong sell." The average consensus recommendation for the it services & consulting peer group is also "buy"
Wall Street's median 12-month price target for Dynatrace, Inc is $49.00, about 6.7% above its last closing price of $45.71
This summary was machine generated from LSEG data August 5 at 02:16 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | 0.45 | 0.48 | Beat |
Mar. 31 2026 | 0.39 | 0.41 | Beat |
Dec. 31 2025 | 0.41 | 0.44 | Beat |
Sep. 30 2025 | 0.41 | 0.44 | Beat |
Recent news on Dynatrace
See all newsUS RESEARCH ROUNDUP-Biogen, Datadog, Tesla
Brief: Dynatrace Units Enter Credit Agreement For Revolving Facility Up To $500 Million
U.S. STOCKS ON THE MOVE-Dynatrace, Cava Group, Halozyme Therapeutics
U.S. STOCKS ON THE MOVE-Halozyme Therapeutics, Etsy, Netflix
Dynatrace shares gain; Needham upgrades to 'buy'